|
There are a variety of approaches
to create second generation biologics, including
incorporating the unique properties of synthetic antibodies,
or bi-specific targeting. These features, as well as
optimization methods for improving the characteristics of
therapeutic proteins, will be explored. Functional
diversity, as well as new classes of drugs, will be
showcased, along with the latest technologies for generating
and screening diverse compound libraries. Plan to attend to
get up to speed on the newest trends in antibodies and
peptide engineering.
Scientific Advisory Board
H. Kaspar Binz, Ph.D., Vice President Technology, Molecular
Partners AG
Andrew M. Bradbury, M.B. B.S., Ph.D., Staff Scientist,
Biosciences, Los Alamos National Laboratory
Michael J. Feldhaus, Ph.D., Senior Director, Antibody
Engineering, Adimab Inc.
Lutz Jermutus, Ph.D., Director of Research - Technology,
MedImmune Ltd.
Aaron K. Sato, Ph.D., Senior Director, OncoMed
Pharmaceuticals, Inc.
Sachdev Sidhu, Ph.D., Banting & Best Medical Research,
University of Toronto
Richard W. Wagner, Ph.D., President and Chief Executive
Officer, SRU Biosystems, Inc.
Gregory A. Weiss, Ph.D., Associate Professor, Department of
Chemistry, Molecular Biology & Biochemistry, University
of California, Irvine
K. Dane Wittrup, Ph.D., J.R. Mares Professor, Chemical
Engineering & Bioengineering, Massachusetts Institute of
Technology
|
KEYNOTE PRESENTATION |
|
Biologics and Healthcare
Mark Levick, M.D., Ph.D., Global Head, Biologics Unit,
Novartis Institutes for BioMedical Research (NIBR)
George D. Yancopoulos, M.D., Ph.D., President, Research
Laboratories & Chief Scientific Officer, Regeneron
Pharmaceuticals Inc. |
Library
Design and Engineering-
Expanding
on Diversity
Phylomers: Peptides Derived from Biodiverse Genomes, as
Blockers for Intracellular as Well as Extracellular Targets
Paul Watt, Ph.D., Vice President, Research, Phylogica Ltd.
Use of Phage Display to Develop Therapeutic Antibodies for
the Treatment of TTP, a Potentially Fatal Autoimmune
Thrombotic Disorder
Don Siegel, M.D., Ph.D., Professor and Vice-Chair,
Department of Pathology & Laboratory Medicine,
University of Pennsylvania School of Medicine
Screening
on Cells and Complex Organisms
Cell Panning and Development of a Bispecific Antibody
Wei Yan, Ph.D., Principal Scientist, Protein Science, Amgen
Sorting on Cells and Complex Organisms
James D. Marks, M.D., Ph.D., Professor, Anesthesia &
Pharmaceutical Chemistry, University of California, San
Francisco
Bi-Specific
Antibodies
Fc-engineered CD19 x CD32b Antibody for B Cell Inhibition in
Autoimmune Diseases
John Desjarlais, Ph.D., Vice President of Research, Protein
Engineering, Xencor
Using Computational Modeling and Simulation to Guide the
Development of Novel Bispecific Antibodies Against the ErbB
Network
Brian D. Harms, Ph.D., Senior Scientist, Computational
Biology, Merrimack Pharmaceuticals, Inc.
Multi-specific or Multivalent IgG Antibodies with Engineered
Antigen Binding Sites in the Constant Domains of Heavy
and/or Light Chains
Geert C. Mudde, Ph.D., Chief Scientific Officer, F star
Stability Engineered IgG-Like Tetravalent Antibody
Brian R. Miller, Ph.D., Scientist II, Protein Engineering,
Biogen Idec
Use
of Phage Display to Address Difficult Targets:
Transmembrane and Intracellular
Selection of Antibodies Against Multispan Membrane Proteins
from Phage Display Libraries
Isidro Hotzel, Ph.D., Scientist, Antibody Engineering,
Genentech, Inc.
Alternative
Display Systems
Mammalian Surface Display
David Wenyan Shen, Ph.D., Executive Director and Head,
Biologics Research and GlycoFi, Merck & Co., Inc.
mRNA Display Design of High Affinity Binding Proteins:
Biology, Diagnostics, and Therapy
Richard W. Roberts, Ph.D., Associate Professor, Chemistry
& Chemical Engineering, University of Southern
California
Case
Studies From Phage Display to the Clinic
A Potent Anti-Notch1 Antibody Specifically Blocks the Ligand
Binding Site and Inhibits Multiple Notch Dependent
Processes, Including Tumor Growth
Aaron K. Sato, Ph.D., Senior Director, OncoMed
Pharmaceuticals, Inc.
Targeting GM-CSF-R: Why High Affinity Matters
Matthew Sleeman, Ph.D., Director, Respiratory, Inflammation
and Autoimmunity Department, MedImmune, Inc.
For questions, please contact:
Christina Lingham
Executive Director, Conference
Cambridge Healthtech Institute
Fax: 781-972-5425
E-mail: clingham@healthtech.com
For sponsorship and exhibit information, contact:
Carol Dinerstein
Cambridge Healthtech Institute
Phone: 781-972-5471
E-mail: dinerstein@healthtech.com
|
